BR112012009182A2 - photointegrated nanoparticles for cell and tissue bleaching - Google Patents

photointegrated nanoparticles for cell and tissue bleaching

Info

Publication number
BR112012009182A2
BR112012009182A2 BR112012009182-4A BR112012009182A BR112012009182A2 BR 112012009182 A2 BR112012009182 A2 BR 112012009182A2 BR 112012009182 A BR112012009182 A BR 112012009182A BR 112012009182 A2 BR112012009182 A2 BR 112012009182A2
Authority
BR
Brazil
Prior art keywords
ligand
composition
particles
protecting group
photo
Prior art date
Application number
BR112012009182-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Dvir Tal
S. Kohane Daniel
Ryan Banghart Matthew
S. Langer Robert
Original Assignee
Massachusetts Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute Of Technology filed Critical Massachusetts Institute Of Technology
Publication of BR112012009182A2 publication Critical patent/BR112012009182A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112012009182-4A 2009-09-30 2010-09-30 photointegrated nanoparticles for cell and tissue bleaching BR112012009182A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24753509P 2009-09-30 2009-09-30
US61/247.535 2009-09-30
PCT/US2010/050846 WO2011041496A1 (en) 2009-09-30 2010-09-30 Phototriggered nanoparticles for cell and tissue targeting

Publications (1)

Publication Number Publication Date
BR112012009182A2 true BR112012009182A2 (en) 2018-03-20

Family

ID=43826645

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012009182-4A BR112012009182A2 (en) 2009-09-30 2010-09-30 photointegrated nanoparticles for cell and tissue bleaching

Country Status (12)

Country Link
US (1) US20130004522A1 (https=)
EP (1) EP2482922A1 (https=)
KR (1) KR20120080615A (https=)
CN (1) CN102883773A (https=)
AU (1) AU2010300629A1 (https=)
BR (1) BR112012009182A2 (https=)
CA (1) CA2780137C (https=)
IL (1) IL218964A0 (https=)
IN (1) IN2012DN03178A (https=)
MX (1) MX2012003990A (https=)
RU (1) RU2012117418A (https=)
WO (1) WO2011041496A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1795257B1 (en) 2003-07-17 2013-05-08 Unilever N.V. Method of stabilizing an edible dispersion comprising oil
EP1850676A1 (en) 2005-02-17 2007-11-07 Unilever N.V. Granules comprising sterol
US20110218123A1 (en) 2008-09-19 2011-09-08 President And Fellows Of Harvard College Creation of libraries of droplets and related species
PL2367434T3 (pl) 2008-12-19 2017-09-29 Unilever BCS Europe B.V. Jadalne tłuszczowe proszki
PL2584907T3 (pl) 2010-06-22 2014-10-31 Unilever Bcs Europe Bv Proszek jadalnego tłuszczu
US20130266715A1 (en) 2010-12-17 2013-10-10 René Joachim Buter Process of compacting a microporous fat powder and compacted fat powder so obtained
MX342040B (es) 2010-12-17 2016-09-12 Unilever Nv Emulsion de agua en aceite comestible.
EP3065712A4 (en) 2013-11-08 2017-06-21 President and Fellows of Harvard College Microparticles, methods for their preparation and use
CN103623417B (zh) * 2013-12-18 2016-01-20 东华大学 一种功能化聚酰胺-胺树状大分子的纳米复合物的应用
CA3001679A1 (en) 2015-10-13 2017-04-20 President And Fellows Of Harvard College Systems and methods for making and using gel microspheres
WO2021002131A1 (ja) * 2019-07-01 2021-01-07 富士フイルム株式会社 半導体膜、光電変換素子、イメージセンサおよび半導体膜の製造方法
KR20210149956A (ko) * 2020-06-02 2021-12-10 삼성디스플레이 주식회사 양자점 조성물, 발광 소자 및 이의 제조 방법
CN114574187B (zh) * 2020-11-30 2024-03-05 北京京东方技术开发有限公司 纳米粒子、纳米粒子层图案化的方法及相关应用
WO2022134039A1 (zh) * 2020-12-25 2022-06-30 京东方科技集团股份有限公司 量子点材料、发光器件及其制作方法、显示装置
US20240306412A1 (en) * 2021-02-23 2024-09-12 Beijing Boe Technology Development Co., Ltd. Quantum dot light-emitting device and manufacturing method therefor, and display apparatus
US12187935B1 (en) * 2023-12-12 2025-01-07 Applied Materials, Inc. Liquid dispersion of quantum dots in an acrylic monomer medium

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998580A (en) * 1995-10-13 1999-12-07 Fay; Frederick F. Photosensitive caged macromolecules
US20070041934A1 (en) * 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
US20080318246A1 (en) * 2007-03-07 2008-12-25 The Albert Einstein College Of Medicine Of Yeshiva University Deeply quenched enzyme sensors

Also Published As

Publication number Publication date
IN2012DN03178A (https=) 2015-09-25
EP2482922A1 (en) 2012-08-08
CN102883773A (zh) 2013-01-16
WO2011041496A1 (en) 2011-04-07
KR20120080615A (ko) 2012-07-17
AU2010300629A1 (en) 2012-06-21
IL218964A0 (en) 2012-06-28
CA2780137A1 (en) 2011-04-07
US20130004522A1 (en) 2013-01-03
RU2012117418A (ru) 2013-11-10
MX2012003990A (es) 2012-06-27
CA2780137C (en) 2014-07-22

Similar Documents

Publication Publication Date Title
CA2780137C (en) Phototriggered nanoparticles for cell and tissue targeting
TWI741064B (zh) 用於修飾介導生物活性或與生物活性有關之靶結構之醫藥組合物及套組
Li et al. Near-infrared light-triggered release of small molecules for controlled differentiation and long-term tracking of stem cells in vivo using upconversion nanoparticles
Mitragotri et al. Accelerating the translation of nanomaterials in biomedicine
Dvir et al. Photo-targeted nanoparticles
TWI574712B (zh) 利用電漿子增強之光譜療法（ｐｅｐｓｔ）及激子-電漿增強之光療法（ｅｐｅｐ）治療細胞增生病症之組合物及產生自體疫苗之系統
Logothetidis Nanomedicine and nanobiotechnology
Li et al. Cancer cell membrane biomimetic nanosystem for homologous targeted dual-mode imaging and combined therapy
Shah The nanomaterial toolkit for neuroengineering
Tang-Schomer et al. Film interface for drug testing for delivery to cells in culture and in the brain
Chen et al. Advancing oral cancer care: nanomaterial-driven diagnostic and therapeutic innovations
You et al. Adaptive dual-responsive nanocapsules for precision ferroptosis-driven and chemotherapy-enhanced tumor ablation
US20080260725A1 (en) Tag and target delivery system
Guo et al. A review of biomodified or biomimetic polymer dots for targeted fluorescent imaging and disease treatments
US10183081B2 (en) Use of scintillator-based nanoparticles for in vivo control of light-sensitive bioactive molecules
Nazarnezhad et al. Cancer diagnosis and therapy by electrospun nanofibers: Opportunities and challenges
EP4007541A1 (en) A method for locomotion of a nanorobot and implementations thereof
US20250302881A1 (en) Nanomaterial-stem cell composition and methods of use
Jiang Nanobubble-assisted ultrasound theragnostics in cellular immunotherapy for cancers
Dahman et al. Nanotechnology and its Applications in Biomedical Engineering
Schäfer et al. Aptamer-Nanoparticle Bioconjugates for Drug Delivery
CN121513219A (zh) 靶向肿瘤细胞的可控响应纳米材料及其制备方法和应用
Boto Leukemia Cells Modulation by Light-Activatable Nanoparticles

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.